10 March 2011

Australian Securities Exchange
Announcement

Australasian Lymphology Association - Time to Move with Lymphoedema

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

Brisbane, Australia. – ImpediMed Limited (“ImpediMed” or the “Company”) refers to a recent announcement in the Australian marketplace regarding bioimpedance spectroscopy - BIS.

We applaud the Australasian Lymphology Association (ALA) for its continued efforts to advance community awareness and improve the quality of care for the condition of lymphoedema.

The relevance of the ALA’s media release to the Company and our shareholders is their independent Australian recognition of BIS and its role in aiding in the early detection of lymphoedema. ImpediMed’s L-Dex® U400 device is built on a BIS platform that was born out of the collaborative efforts between the University of Queensland, Dr. Leigh Ward and the Queensland University of Technology, Dr Bruce Cornish.

As our shareholders are aware, ImpediMed’s U400 has a CE Mark and is a TGA listed device for sale in the European and Australian markets as an aid in the diagnosis of early lymphoedema.

Please find the link to the Australasian Lymphology Association (ALA) media release for lymphoedema awareness month below – reference to BIS testing.


Enquiries about this release should be directed to ImpediMed’s CEO, Greg Brown, on +61 7 3860 3700.

ENDS

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
This announcement has been prepared for publication in Australia and New Zealand and may not be distributed or released in the United States. This announcement does not constitute promotion for the use of BIS devices in the United States or in any other jurisdiction in which such device clearance has not been obtained.